期刊文献+

吡美莫司在小儿特应性皮炎中的应用

原文传递
导出
摘要 特应性皮炎是瘙痒非常剧烈的一种慢性湿疹皮炎类皮肤病。通常在儿童早期发病,迄今尚无特效治疗特应性皮炎的方法,对特应性皮炎的治疗目标仅限于缓解症状、减轻皮肤炎症和减少疾病严重发作。儿童患者因体表面积与体质量比值较大,外用药物系统吸收风险也较大。吡美莫司是近年出现的比较安全和选择性抑制炎症反应过程的药物,多项研究表明吡美莫司治疗小儿特应性皮炎安全有效。
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2009年第6期439-441,共3页 Chinese Journal of Dermatology
  • 相关文献

参考文献21

  • 1Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol, 1999, 141(2): 264-273.
  • 2Hoetzenecker W, Meingassner JG, Eeker R, et al. Corticosteroids but not pimecrolimus affect viability, maturation and immune function of murine epidermal Langerhans cells. J Invest Dermatol, 2004, 122(3): 673-684.
  • 3Alomar A, Berth-Jones J, Bos JD, et al. The role of topical calcineurin inhibitors in atopic dermatitis. Br J Dermatol, 2004, 151(Suppl 70): 3-27.
  • 4Eichenfield LF, Beck L. Elidel (pimecrolimus) cream 1%: a nonsteroidal topical agent for the treatment of atopic dermatitis. J Allergy Clin Immunol, 2003, 111(5): 1153-1168.
  • 5Billich A, Aschauer H, Aszodi A, et al. Percutaneous absorption of drugs used in atopic eczema: pimeerolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm, 2004, 269( 1 ): 29-35.
  • 6Meingassner JG, Aschauer H, Stuetz A, et al. Pimecrolimus permeates less than tacrolimus through normal, inflamed, or corticosteroid-pretreated skin. Exp Dermatol, 2005, 14 (10): 752-757.
  • 7Rappersberger K, Komar M, Ebelin ME, et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol, 2002, 119(4): 876-887.
  • 8Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol, 2001, 144(4): 781-787.
  • 9Allen BR, Lakhanpaul M, Morris A, et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1% in atopic dermatitis patients. Arch Dis Child, 2003, 88: 969-973.
  • 10Staab D, Pariser D, Gottlieb AB, et al. Low systemic absorption and good tolerability of pimecrolimus, administered as 1% cream (Elidel) in infants with atopic dermatitis-a multicenter, 3-week, open-label study. Pediatr Dermatol, 2005, 22 (5): 465-471.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部